Basel based Anaveon is engineering cytokines to solve the problem of T-cell exhaustion

blonca9
Sep 25, 2024
1 min read

Co-Founder & CEO Andreas Katopodis describes the company’s three primary programs: a non-specific fusion protein that blocks the alpha receptor of IL-2 to signal CD8 cells but not T-regs, and two bispecifics that use a non-binding PD-1 as a delivery device to home on to the cancer cells.

Recent Posts

See All

Cambridge, UK based Maxion Therapeutics raised a $72M series A in March to advance its KnotBody programs - which combine the benefits of knottins and antibodies and can target ion channels and GPCRs

ASGCT 2025: HuidaGene presented preclinical and early clinical data for its CRISPR Cas12 based program for DMD in a Presidential Symposium talk

ASGCT 2025: Dyno Therapeutics' CEO Eric Kelsic discusses the latest in capsids for CNS, ophthalmology, and neuromuscular conditions

Basel based Anaveon is engineering cytokines to solve the problem of T-cell exhaustion

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight